Drug intelligence / Profile preview

2',5'-oligoadenylate

Development stage
Preclinical
Lead developer
Oragen
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Inhalation
01

Overview

2',5'-oligoadenylate (2-5A) is a naturally occurring oligonucleotide produced by the interferon-induced enzyme 2',5'-oligoadenylate synthetase (OAS). It is characterized by unique 2',5'-phosphodiester bonds rather than the standard 3',5'-bonds found in most RNA. The molecule serves as a critical second messenger in the innate immune system's antiviral response by binding to and activating Ribonuclease L (RNase L). Once activated, RNase L dimerizes and degrades viral and cellular single-stranded RNA, effectively halting viral replication and protein synthesis. Synthetic analogues of 2-5A, such as Oragen 0004, have been developed to improve stability against phosphodiesterases for potential therapeutic use in treating viral infections (e.g., respiratory syncytial virus, murine hepatitis virus) and metabolic conditions like obesity-related insulin resistance.

Other names
2',5'-linked oligoadenylate2',5'-Appp(A2'p5')nA
02

Targets

RNASEL (Ribonuclease L)

Beyond the preview

Go deeper on 2',5'-oligoadenylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2',5'-oligoadenylate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call